Ongoing serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXHistory of serious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing wound, skin ulcer, or bone fractureXx_NEWLINE_xXPrior osteoporotic fractureXx_NEWLINE_xXSerious nonhealing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fracture within 6 months prior to enrollmentXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXEvidence of a significant uncontrolled concomitant disease of the nervous system, pulmonary, autoimmune, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fractureXx_NEWLINE_xXSerious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to initiation of study treatment;Xx_NEWLINE_xXPatients with serious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPrior major surgery or fracture within 3 weeks prior to randomization or presence of any non-healing wound.Xx_NEWLINE_xXPatients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollmentXx_NEWLINE_xXSerious or non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXPresence of a non-healing wound, or non-healing ulcer, (that is not tumor related) or bone fractureXx_NEWLINE_xXAny patient with a current non-healing wound, bone fracture, or skin ulcer is excludedXx_NEWLINE_xXPatients with serious non-healing wound, ulcer, or bone factor; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinationsXx_NEWLINE_xXPresence of serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollmentXx_NEWLINE_xXSerious, non-healing wound; active ulcer; or untreated bone fractureXx_NEWLINE_xXPresence of any non-healing wound, fracture, or ulcer within 28 days prior to study registration.Xx_NEWLINE_xXPatients with serious or non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXPatients who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment are not eligibleXx_NEWLINE_xXOngoing serious, non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXHave active poor wound healing (delayed healing, wound infection or fistula)Xx_NEWLINE_xXPatients with a serious non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXPresence of non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXAny severe or poorly controlled systemic disease (e.g., hypertension; clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound healing, ulcer or bone fracture)Xx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound or ulcer; bone fracture within 3 months prior to study entryXx_NEWLINE_xXSerious or non-healing wound, ulcer or bone fractureXx_NEWLINE_xXHistory or evidence of arterial thrombotic or hemorrhagic disorders within 3 months before proposed start of treatment, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPatients who have a non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXSerious non-healing wound, ulcer or bone fractureXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fracture.Xx_NEWLINE_xXNon-healing wound, ulcer, non-healing traumatic bone fracture, or abscess within 30 days of enrollment\r\n* Nondisplaced, uncomplicated pathologic fracture due to tumor may be eligible provided adequately treated with radiation, surgery or other treatments with full recovery based upon investigator assessmentXx_NEWLINE_xXHas a known history of non-healing wounds or ulcers, or bone re-fractures within 3 months of fractureXx_NEWLINE_xXNon-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the underlying neoplasm;Xx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXSerious non-healing wound, ulcer or bone fractureXx_NEWLINE_xXNon-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPatients who have serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXhave any non-healing wound, fracture, or ulcer within 28 days prior to the planned start of study treatment;Xx_NEWLINE_xX(Bevacizumab-related exclusion) History of abdominal fistula or gastrointestinal perforation within 6 months prior to the first study treatment. Serious, non-healing wound, active ulcer, or untreated bone fracture (adjuvant trials: bone fractures must be healed)Xx_NEWLINE_xXSerious non-healing or dehiscing wound, active ulcer, or untreated or non-healing bone fractureXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Non-healing wound or ulcerXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fracture, including tumor-related pathological fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer or bone fractureXx_NEWLINE_xXHistory of abdominal fistula or gastrointestinal perforation =< 6 months before cycle 1, day 1; serious non-healing wound, active ulcer, or untreated bone fracture (adjuvant trials: bone fractures must be healed)Xx_NEWLINE_xXNon-healing wound, ulcer, or bone fractureXx_NEWLINE_xXOther clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryXx_NEWLINE_xXSerious, non-healing or dehiscing wound or active ulcerXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXParticipant has a serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXActive wound, a serious or non-healing wound, an active ulcer or untreated bone fractureXx_NEWLINE_xXNon-healing wound, bone fracture, or skin ulcerXx_NEWLINE_xXmCRPC EXPANSION COHORT: Other clinically significant disorders such as:\r\n* Active infection requiring intravenous treatment within 7 days of starting protocol treatment\r\n* Serious non-healing wound/ulcer/bone fracture (excluding stable compression fracture) within 28 days before the first dose of study treatmentXx_NEWLINE_xXNo evidence of a history of wound healing complications prior to study enrollmentXx_NEWLINE_xXIncreased risk of wound dehiscence or presence of non-healing woundsXx_NEWLINE_xXThe patient has a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollmentXx_NEWLINE_xXSerious, non-healing or dehiscing woundXx_NEWLINE_xXNon-healing wound, ulcer, or bone fractureXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Presence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXNon-healing wound, active peptic ulcer or bone fractureXx_NEWLINE_xXThe patient has a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollmentXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or benign bone fracture (patients with stress insufficiency fractures e.g. from osteoporosis or pathological fracture from tumor are eligible for study)Xx_NEWLINE_xXSerious or nonhealing wound, ulcer, bone fracture, or osteonecrosis of the jawXx_NEWLINE_xXSubject has a serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXIncomplete wound healingXx_NEWLINE_xXPresence of any non-healing wound, fracture, or ulcerXx_NEWLINE_xXMust not exhibit a non-healing wound or any skin breakdownXx_NEWLINE_xXPatients who have serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious non-healing wound, active peptic ulcer, or untreated bone fractureXx_NEWLINE_xXPrior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)Xx_NEWLINE_xXSerious non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing wound, ulcer or bone fractureXx_NEWLINE_xXThe patient has a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapyXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXA serious, non healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fracture; any bone fractures must be healedXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXNon-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the underlying neoplasm;Xx_NEWLINE_xXNon healing wound, ulcer or bone fractureXx_NEWLINE_xXNon-healing serious wound, ulcer, or bone fracture unrelated to the primary tumorXx_NEWLINE_xXNon?healing wound, ulcer, or bone fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXPresence of a serious nonhealing wound, ulcer, or bone fractureXx_NEWLINE_xXOngoing significant, uncontrolled medical condition including: o Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.Xx_NEWLINE_xXOther clinically significant disorders such as:\r\n* Active uncontrolled infection requiring intravenous systemic treatment within 14 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n*** In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryXx_NEWLINE_xXHistory of serious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXEvidence of inadequate wound healingXx_NEWLINE_xXPatients with a non-healing wound, fracture, or ulcerXx_NEWLINE_xXNon-healing wound, ulcer or bone fractureXx_NEWLINE_xXPatients with serious non-healing wound, ulcer, or bone fracture within 28 days before registration; patients should not have had any major surgical procedures within 28 days of registrationXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXOther clinically significant disorders such as:\r\n* Active infection requiring systemic treatment\r\n* Serious non-healing wound/ulcer/bone fracture\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\r\n* History of major surgery within 4 weeks or minor surgical procedures within 1 week before randomizationXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXPrior major surgery within the previous 28 days of study registration and/or presence of any non-healing wound, fracture, or ulcerXx_NEWLINE_xXSubjects with a non-healing serious wound, ulcer, or bone fracture unrelated to the primary tumorXx_NEWLINE_xXPatients who have a serious or non-healing wound, ulcer, or bone fracture at the time of study enrollment are not eligibleXx_NEWLINE_xXSerious or non-healing wound, ulcer or bone fractureXx_NEWLINE_xXSerious non-healing wound, ulcer, bone fracture, or abscessXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPatients with a serious or non-healing wound, ulcer, or bone fracture are not eligible for this studyXx_NEWLINE_xXPatients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinationsXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXThe participant has a serious nonhealing: (a) wound, (b) peptic ulcer, or (c) bone fracture.Xx_NEWLINE_xXSerious, non-healing wound, infection, ulcer, bone fracture, or uncontrolled seizuresXx_NEWLINE_xXPatients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollmentXx_NEWLINE_xXPatient must not have serious or non-healing wound, ulcer, or bone fracture at the time of randomizationXx_NEWLINE_xXHas evidence of inadequate wound healing.Xx_NEWLINE_xXPresence of any non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular diseaseXx_NEWLINE_xXPatients are excluded if they have a non-healing wound or ulcerXx_NEWLINE_xXPresence of non-healing wound, non-healing ulcer, or bone fracture.Xx_NEWLINE_xXHave had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.Xx_NEWLINE_xXSerious non-healing wound, ulcer or bone fractureXx_NEWLINE_xXPatients with serous non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fracture requiring surgical intervention.Xx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing or dehiscing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXNon-healing wound, ulcer or bone fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fracture.Xx_NEWLINE_xXHas history of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to entry in to the trialXx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fracture as judged by treating physicianXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPatients with a history of a serious non-healing wound, ulcer, or bone fracture are not eligibleXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing wound, active ulcer or bone fractureXx_NEWLINE_xXNon-healing wound, ulcer or bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fracture as so judged by the treating physicianXx_NEWLINE_xXPresence of a non-healing wound or non-healing ulcer that is not tumor relatedXx_NEWLINE_xXSubjects who have an active clinically serious infection of CTCAE Grade ?2 or non-healing wound unrelated to the primary Tumor.Xx_NEWLINE_xXPresence of any non-healing wound, fracture, or ulcer within 28 days prior to the first dose of study drug.Xx_NEWLINE_xXOther clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatmentXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXNon-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPresence of any non-healing wound, fracture, or ulcer within 28 days prior to study registration.Xx_NEWLINE_xXHas a history of non-healing wounds or ulcers, or bone refractures within 3 months of fractureXx_NEWLINE_xXPatients with serious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXNon-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPatients with serious non-healing wound, ulcer, or bone fracture, including history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinationsXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXPresence of a non-healing wound or non-healing ulcer that is not tumor relatedXx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXOngoing serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXOngoing serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing wound, skin ulcer, or bone fracture.Xx_NEWLINE_xXSerious, non-healing or dehiscing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXParticipants who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollmentXx_NEWLINE_xXPrior major surgery or trauma within 28 days and/or presence of any non-healing wound, fracture or ulcer (procedures such as catheter placement not considered to be major)Xx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXPatients with a serious, non-healing wound, ulcer, or bone fracture are not eligible for participationXx_NEWLINE_xXNon-healing wound, bone fracture or skin ulcerXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXNo history of serious (i.e., requiring active medical therapy with medication or medical device under the supervision of a physician) non-healing wound, ulcer, trauma, or bone fracture within 28 days prior to study entryXx_NEWLINE_xXNon-healing wound, ulcer or fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing wound, ulcer or bone fractureXx_NEWLINE_xXHistory of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registrationXx_NEWLINE_xXPatient must not have prior major surgery, trauma, presence of any non-healing wound, fracture, or ulcer within 28 days prior to first dose of study drugXx_NEWLINE_xXNon-healing wound, ulcer (including gastrointestinal), or fractureXx_NEWLINE_xXSerious or non-healing wound, ulcer or bone fracture; if patient develops a serious or non-healing wound, ulcer or bone fracture after enrollment, but prior to study drug initiation, patient is not eligible to begin protocol therapyXx_NEWLINE_xXNon-healing wound, ulcer or bone fractureXx_NEWLINE_xXNo serious non-healing wound, ulcer or bone fractureXx_NEWLINE_xXPrior major surgery or trauma within 28 days prior to registration and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major); if the patient has a compression fracture secondary to tumor this should be treated and 28 days elapsed prior to entry on the protocolXx_NEWLINE_xXPrior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)Xx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXSerious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXMajor surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer not related to cancer (procedures such as catheter placement not considered to be major)Xx_NEWLINE_xXOther clinically significant disorders such as:\r\n* Active infection requiring systemic treatment\r\n* Serious non-healing wound/ulcer/bone fracture\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\r\n* History of major surgery within 4 weeks or minor surgical procedures within 1 week before randomizationXx_NEWLINE_xXHistory of serious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPrior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)Xx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXSerious, non-healing woundXx_NEWLINE_xXPrior major surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)Xx_NEWLINE_xXPatients with a history of non-healing wounds or ulcers, or bone refractures within 3 months of fractureXx_NEWLINE_xXNon-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPatients with documented chronic non-healing wound, ulcer or bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fracture; patients with any wound requiring surgical intervention (including scalp wounds requiring cranioplasty) will be allowed to resume the study if the wound is clean and without further infection post-surgical interventionXx_NEWLINE_xXSubject has a serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing active wound, ulcer, or bone fractureXx_NEWLINE_xXSerious non-healing wound, active ulcer, or unhealed bone fracture.Xx_NEWLINE_xXPatients with serious non-healing wound, ulcer, or untreated bone fracture. This includes a history of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1. Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations until closure.Xx_NEWLINE_xXSerious or non-healing wound, ulcer or bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXNon-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXSerious non-healing wound or ulcer on scalpXx_NEWLINE_xXSevere acute infection; serious non-healing wound or ulcer on scalpXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing skin ulcer, or bone fractureXx_NEWLINE_xXPresence of a non-healing wound or bone fractureXx_NEWLINE_xXPrior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)Xx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXPrior major surgery or trauma within 28 days prior to the protocol-mandated 4-week drug holiday and/or presence of any non-healing wound, fracture, or ulcer.Xx_NEWLINE_xXPatients with a serious non-healing wound ulcer, or bone fracture, or major surgical procedure within 21 days prior to starting treatmentXx_NEWLINE_xXNon-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXEvidence of significant uncontrolled concomitant diseases, such as ocular toxicities, diabetes, cardiovascular disease; nervous system, renal, hepatic, endocrine, or gastrointestinal disorders; autoimmune disease, or a serious non-healing wound or fractureXx_NEWLINE_xXHave a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to receiving study drugs.Xx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fracture.Xx_NEWLINE_xXUncontrolled diabetes, active liver disease, poorly controlled chronic obstructive pulmonary disease, serious or non-healing wound, ulcer, or fracture;Xx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSevere, nonhealing or open wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXSerious and non-healing wound, active ulcer, or untreated bone fracture.Xx_NEWLINE_xXNon-healing wound, ulcer, or bone fractureXx_NEWLINE_xXPatients must not have a non-healing wound or fractureXx_NEWLINE_xXPresence of any non-healing wound, fracture, or ulcerXx_NEWLINE_xXNon-healing wound, skin ulcer, or bone fractureXx_NEWLINE_xXAny medical condition that requires intact wound healing capacity and is expected to endanger participant safety if wound healing capacity would be severely reduced during administration of the investigational agentXx_NEWLINE_xXSerious or non-healing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXSerious, non-healing wound, skin ulcer (of any grade), or bone fracture.Xx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious or non-healing active wound, ulcer, or bone fractureXx_NEWLINE_xXOngoing serious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXNon-healing wound, ulcer (including gastrointestinal), or fractureXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or untreated bone fracture; bone fractures must be healedXx_NEWLINE_xXEvidence of significant uncontrolled concomitant diseases, such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fractureXx_NEWLINE_xXPrior major surgery or trauma within 28 days prior to the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.Xx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious non-healing wound, ulcer, or active bone fracture;Xx_NEWLINE_xXSerious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXHas had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomizationXx_NEWLINE_xXSerious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomizationXx_NEWLINE_xXPatients with serious non-healing wound, ulcer or bone fracture; this includes history of abdominal fistula or intra-abdominal abscess within 6 months; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinationsXx_NEWLINE_xXPrior major surgery or trauma within 14 days of the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcerXx_NEWLINE_xXSerious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXIncomplete wound healingXx_NEWLINE_xXA serious, non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXMajor surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcerXx_NEWLINE_xXPatients who have not recovered from the surgical resection of rectal cancer such as wound dehiscence, non-healing wound, wound infection and fistulaXx_NEWLINE_xXSerious, non-healed wound, ulcer, or bone fractureXx_NEWLINE_xXNo history of serious non-healing wound, ulcer, or bone fracturesXx_NEWLINE_xXSerious, non-healing or dehiscing wound or active ulcerXx_NEWLINE_xXAny serious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing wound, active ulcer, or unhealed bone fractureXx_NEWLINE_xXPresence of a non-healing wound, non-healing ulcer, or bone fractureXx_NEWLINE_xXSerious, non-healing or dehiscing wound, active ulcer, or untreated bone fractureXx_NEWLINE_xXPatients with serious, non-healing wound, ulcer or bone fracture (other than pathologic fracture)Xx_NEWLINE_xXSerious, non-healing or dehiscing wound or active ulcerXx_NEWLINE_xXHistory of recent fracture (within 3 months of recruitment), complicated non-healing fracture, hip arthroplasty, knee arthroplastyXx_NEWLINE_xXPatient must not have prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)Xx_NEWLINE_xXPatient must not have a serious or non-healing wound, ulcer, or bone fractureXx_NEWLINE_xX